natgillin/translations-raw huggingface dataset:
Dolutegravir had no Pharmacodynamic effect on Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and progesterone.
Dolutegravir ni imel farmakodinamičnega učinka na luteinizirajoči hormon (LH), folitropin (FSH) in progesteron.
There are limited data available on the use of dolutegravir, abacavir and lamivudine in patients aged 65 years and over.
Na voljo so omejeni podatki o uporabi dolutegravirja, abakavirja in lamivudina pri bolnikih, starih 65 let ali več.
At 96 weeks, virologic suppression in the dolutegravir group (80%) was superior to the DRV/r group (68%), (adjusted treatment difference [DTG-(DRV+RTV)]: 12.4%; 95% CI: [4.7, 20.2]).
Po 96 tednih je bila virološka supresija v skupini z dolutegravirjem (80 %) superiorna tisti v skupini z DRV/r (68 %) (korigirana razlika med zdravljenjema [DTG-(DRV+RTV)]: 12,4 %, 95 % IZ: [4,7;
STRIIVING (201147) is a 48-week, randomized, open-label, active controlled, multicenter, noninferiority study in patients without any prior treatment failure, and without any documented resistance to any class.
STRIIVING (201147) je 48-tedenska, randomizirana, odprta, z zdravilno učinkovino nadzorovana, multicentrična študija neinferiornosti pri bolnikih brez kakšnega neuspeha predhodnega zdravljenja in brez dokumentirane odpornosti proti kateri koli skupini.
If you have stopped taking Triumeq for any reason - especially because you think you are having side effects, or because you have other illness:
Če ste zdravilo Triumeq prenehali jemati zaradi kakršnega koli razloga - še zlasti, če menite, da imate neželene učinke, ali ker imate druge bolezni:
It is unknown if all or part of this is due to unabsorbed active substance or biliary excretion of the glucuronidate conjugate, which can be further degraded to form the parent compound in the gut lumen.
Ni znano, ali je vsa ta količina ali pa samo njen del neabsorbirana zdravilna učinkovina ali pa je posledica biliarnega izločanja glukuronidnega konjugata, ki se v črevesni svetlini razgradi, tako da nastane izhodna spojina.
The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5'-carboxylic acid and 5'-glucuronide which account for about 66% of the administered dose.
Pri človeku se abakavir v glavnem presnavlja z alkoholno dehidrogenazo in glukuronidacijo, pri čemer nastane 5'-karboksilna kislina in 5'-glukuronid, ki predstavljata približno 66% prejetega odmerka.
Some people taking Triumeq or other combination treatments for HIV are more at risk of serious side effects than others.
Pri nekaterih ljudeh, ki jemljejo zdravilo Triumeq ali druga kombinirana zdravila za zdravljenje okužbe z virusom HIV, obstaja večje tveganje za pojav resnih neželenih učinkov kot pri drugih.
HLA-B*5701 screening for risk of ABC hypersensitivity should never be substituted for appropriate clinical vigilance and patient management in individuals receiving ABC.
Presejanje za prisotnosti HLA-B*5701 za ugotavljanje tveganja preobčutljivostne reakcije na ABC ne sme nikoli nadomestiti ustreznega kliničnega nadzora in vodenja bolnika pri posameznikih, ki prejemajo ABC.
Dolutegravir is also a substrate of UGT1A3, UGT1A9, CYP3A4, Pglycoprotein (P-gp), and breast cancer resistance protein (BCRP).
Dolutegravir je tudi substrat UGT1A3, UGT1A9, CYP3A4, P-glikoproteina (P-gp) in proteina odpornosti pri raku dojke (BCRP).
Virologic non response† No virologic data at Weeks 48 window
Virološki neodziv† V 48. tednu ni viroloških podatkov
In vivo, dolutegravir may increase plasma concentrations of medicinal products in which excretion is dependent upon OCT2 or MATE-1 (e.g. metformin) (see Table 1).
In vivo lahko dolutegravir zviša plazemske koncentracije zdravil, katerih izločanje je odvisno od OCT2 ali MATE-1 (npr. metformin) (glejte Preglednico 1).
Abacavir and lamivudine triphosphates show significantly less affinity for host cell DNA polymerases.
Abakavir in lamivudin trifosfat imata občutno manjšo afiniteto do DNK polimeraz gostiteljske celice.
Similar studies were not conducted with either abacavir or lamivudine.
Podobnih študij, bodisi z abakavirjem bodisi z lamivudinom niso, izvajali.
The combination of abacavir and lamivudine has demonstrated antiviral activity in cell culture against non-subtype B isolates and HIV-2 isolates with equivalent antiviral activity as for subtype B isolates.
Kombinacija abakavirja in lamivudina je v celični kulturi delovala protivirusno proti izolatom podtipa ne-B in izolatom HIV-2 z enakovredno protivirusno aktivnostjo kot pri izolatih podtipa B.
• a decreased number of cells involved in blood clotting (thrombocytopenia).
• zmanjšano število celic, ki sodelujejo pri strjevanju krvi (trombocitopenija)
Triumeq contains dolutegravir, abacavir and lamivudine, therefore any interactions identified for these individually are relevant to Triumeq.
Zdravilo Triumeq vsebuje dolutegravir, abakavir in lamivudin, zato je katera koli interakcija, povezana s posamezno zdravilno učinkovino, relevantna tudi za zdravilo Triumeq.
Antidiabetics Metformin/Dolutegravir
Antidiabetiki metformin/dolutegravir metformin dolutegravir
If you have discontinued Triumeq due to this reaction, YOU MUST NEVER TAKE Triumeq, or any medicine containing abacavir again as within hours you may experience a life-threatening lowering of your blood pressure or death.
Če ste zdravilo Triumeq nehali jemati zaradi te reakcije, NE SMETE NIKOLI VEČ VZETI tega zdravila ali katerega koli zdravila, ki vsebuje abakavir, saj lahko v nekaj urah pride do življenjsko nevarnega znižanja krvnega tlaka ali smrti.
Hypersensitivity case studies
Študije primerov preobčutljivosti
Both abacavir and lamivudine are metabolised sequentially by intracellular kinases to the respective 5'-triphosphates (TP) which are the active moieties with extended intracellular half-lives supporting once daily dosing (see section 5.2).
Oba, tako abakavir kot lamivudin, se dosledno presnavljata z znotrajceličnimi kinazami v ustrezne 5'-trifosfate (TP), ki so aktivne oblike s podaljšano znotrajcelično razpolovno dobo, kar omogoča odmerjanje enkrat na dan (glejte poglavje 5.2).
In this condition, parts of the bone tissue die because of reduced blood supply to the bone.
Pri tej bolezni deli kostnega tkiva odmrejo zaradi zmanjšane prekrvitve kosti.
HLA-B*5701 is the only identified pharmacogenetic marker that is consistently associated with clinical diagnosis of an ABC HSR reaction.
Prisotnost alela HLA-B*5701 je edini znani farmakogenetski označevalec, ki je dosledno povezan s klinično diagnozo preobčutljivostne reakcije na ABC.
The efficacy of Triumeq in HIV-infected, therapy naive subjects is based on the analyses of data from a number of trials.
Učinkovitost zdravila Triumeq pri predhodno nezdravljenih osebah, okuženih z virusom HIV, temelji na analizi podatkov številnih preskušanj.
The systemic exposure at the no effect level in mice and rats was equivalent to 3 and 7 times the human systemic exposure during therapy.
Sistemska izpostavljenost, ki na miših in podganah ni imela še nobenega karcinogenega učinka, je bila ekvivalentna 3-kratni oziroma 7kratni sistemski izpostavljenosti med zdravljenjem človeka.
If you get any symptoms of infection and inflammation or if you notice any of the symptoms above: → Tell your doctor immediately.
Če se pri vas pojavijo simptomi okužbe in vnetja ali če opazite katerega od zgoraj naštetih simptomov:
Clinically it is not possible to determine whether a HSR with Triumeq would be caused by abacavir or dolutegravir.
Klinično ni mogoče ugotoviti ali bi reakcijo pri zdravilu Triumeq povzročil abakavir ali dolutegravir.
Abacavir is metabolised by UGT (UGT2B7) and alcohol dehydrogenase; co-administration of inducers (e.g. rifampicin, carbamazepine and phenytoin) or inhibitors (e.g. valproic acid) of UGT enzymes or with compounds eliminated through alcohol dehydrogenase could alter abacavir exposure.
Abakavir se presnavlja z UGT (UGT2B7) in alkoholno dehidrogenazo; sočasna uporaba induktorjev (npr. rifampicina, karbamazepina in fenitoina) ali zaviralcev (npr. valprojske kisline) encimov UGT ali s sestavinami, ki se izločajo z alkoholno dehidrogenazo, lahko spremeni izpostavljenost abakavirju.
Other signs and symptoms that have been observed as part of abacavir HSR are described in detail in section 4.8 (Description of selected adverse reactions), including respiratory and gastrointestinal symptoms.
Drugi znaki in simptomi, ki so jih opazili v sklopu preobčutljivostnih reakcij na abakavir in so podrobno opisani v poglavju 4.8 (Opis izbranih neželenih učinkov), vključujejo respiratorne in gastrointestinalne simptome.
In patients with prior failed therapies, but naïve to the integrase class (SAILING study), integrase inhibitor substitutions were observed in 4/354 patients (follow-up 48 weeks) treated with dolutegravir, which was given in combination with an investigator selected background regimen (BR).
Pri bolnikih s predhodno neuspešnimi terapijami, ki pa še niso bili zdravljeni z zdravili iz skupine zaviralcev integraz (študija SAILING), so substitucije zaviralcev integraz opazili pri 4/354 bolnikov (spremljanje 48 tednov), zdravljenih z dolutegravirjem v kombinaciji z osnovno shemo (OS), ki jo je izbral raziskovalec.
In serial passage with strain NL432-based site directed mutants at N155H or E92Q, no further selection of resistance was seen (fold change unchanged around 1).
V zaporednem prehodu s sevom NL432, začenši s točkovnimi mutanti, ki vključujejo N155H ali E92Q, ni bilo opaziti nadaljnje selekcije odpornosti (sprememba občutljivosti nespremenjena, okoli 1).
The median time to viral suppression was shorter with ABC/3TC + DTG (28 vs 84 days, p<0.0001).
Mediana časa do virusne supresije v skupini, ki je prejemala ABC/3TC + DTG, je bila krajša (28 proti 84 dni, p<0,0001).
Triumeq can be taken with or without food.
Zdravilo Triumeq se lahko vzame s hrano ali brez nje.
Before you are prescribed Triumeq your doctor will arrange a test to find out whether you carry a particular type of gene called HLA-B*5701.
Preden vam bodo predpisali zdravilo Triumeq, bo vaš zdravnik opravil testiranje, da ugotovi ali ste morda nosilec gena, ki se imenuje HLA-B*5701.
Based on in vivo and/or in vitro data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of any major enzyme or transporter such as CYP3A4, CYP2C9 and P-gp (for more information see section 5.2).
Na podlagi in vivo in/ali in vitro podatkov ni pričakovati, da bi dolutegravir vplival na farmakokinetiko zdravil, ki so substrati glavnih encimov ali prenašalcev, kot so CYP3A4, CYP2C9 in P-gp (za več informacij glejte poglavje
• Extreme tiredness or achiness or generally ill feeling
• huda utrujenost ali bolečnost ali splošno slabo počutje
Active renal secretion of lamivudine in the urine is mediated through the organic cation transporter (OCT) 2 and multidrug and toxin extrusion transporters (MATE1 and MATE2-K).
Aktivno ledvično izločanje lamivudina v urinu posreduje organski kationski prenašalec (OCT) 2 ter prenašalci za ekstruzijo več zdravil in toksinov (MATE1 in MATE-2K).
In dolutegravir Phase III studies patients with hepatitis B and/or C co-infection were permitted to enrol provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal (ULN).
V študijah faze III z dolutegravirjem so bolniki s sočasno okužbo z virusom hepatitisa B in/ali C smeli biti vključeni v študijo pod pogojem, da njihove izhodiščne vrednosti jetrnih testov niso presegle petkratne zgornje meje normale (ULN - upper limit of normal).
§ Includes reasons such as withdrew consent, loss to follow-up, moved, protocol deviation.
§ Vključuje razloge, kot so umik soglasja, prenehanje spremljanja, preselitev, odstopanje od protokola.
Although abacavir and lamivudine are substrates of BCRP and P-gp in vitro, given the high absolute bioavailability of abacavir and lamivudine, (see section 5.2), inhibitors of these efflux transporters are unlikely to result in a clinically relevant impact on abacavir or lamivudine concentrations.
Čeprav sta abakavir in lamivudin in vitro substrata BCRP in P-gp, glede na njuno veliko absolutno biološko uporabnost (glejte poglavje 5.2) ni verjetno, da bi zavrtje teh efluksnih prenašalcev klinično pomembno vplivalo na koncentracijo abakavirja ali lamivudina.
Co-administration of Triumeq and other medicinal products that inhibit UGT1A1, UGT1A3, UGT1A9, CYP3A4, and/or P-gp may therefore increase dolutegravir plasma concentration.
Sočasno jemanje zdravila Triumeq in drugih zdravil, ki zavirajo UGT1A1, UGT1A3, UGT1A9, CYP 3A4 in/ali P-gp, lahko zato poveča plazemske koncentracije dolutegravirja.
Triumeq is recommended to be administered 2 hours before or 6 hours after taking supplements or multivitamins containing calcium, iron or magnesium (see section 4.5).
Zdravilo Triumeq je priporočljivo vzeti 2 uri pred ali 6 ur po uporabi dodatkov ali multivitaminskih pripravkov, ki vsebujejo kalcij, železo ali magnezij (glejte poglavje 4.5).
No Triumeq dosage adjustment necessary, unless patient has renal impairment (See Section 4.2).
Odmerka zdravila Triumeq ni potrebno prilagajati, razen če ima bolnik okvaro ledvic (glejte poglavje 4.2).
If you have stopped taking Triumeq for any reason - especially because you think you are having side effects, or because you have another illness:
Če ste zdravilo Triumeq prenehali jemati zaradi kakršnega koli razloga - še zlasti če menite, da imate neželene učinke, ali ker imate kako drugo bolezen:
Almost all patients developing hypersensitivity reactions will have fever and/or rash (usually maculopapular or urticarial) as part of the syndrome, however reactions have occurred without rash or fever.
Skoraj vsi bolniki, ki bodo razvili preobčutljivostne reakcije, bodo imeli v sklopu tega sindroma povišano telesno temperaturo in/ali izpuščaj (običajno makulopapularni ali urtikarijski), vendar pa so se pojavile tudi reakcije brez izpuščaja ali povišane telesne temperature.
What Triumeq looks like and contents of the pack Triumeq film-coated tablets are purple, biconvex, oval tablets, debossed with “572 Trı” on one side.
Izgled zdravila Triumeq in vsebina pakiranja Filmsko obložene tablete zdravila Triumeq so vijolične, bikonveksne, ovalne tablete z vtisnjeno oznako ‘572 Trı' na eni strani.
48 weeks DTG 50 mg + ABC/3TC once daily N=414
48 tednov DTG 50 mg + ABC/3TC enkrat na dan N=414
rash, pruritus, alopecia1
izpuščaj, srbenje, alopecija
Similar reactions have also occurred infrequently after restarting abacavir in patients who had only one of the key symptoms of hypersensitivity (see above) prior to stopping abacavir; and on very rare occasions have also been seen in patients who have restarted therapy with no preceding symptoms of a HSR (i.e., patients previously considered to be abacavir tolerant).
Podobne reakcije po ponovni uvedbi abakavirja so se redkeje pojavile tudi pri bolnikih z enim samim ključnim simptomom preobčutljivosti (glej zgoraj) pred ukinitvijo abakavirja, v zelo redkih primerih pa tudi pri bolnikih, pri katerih je bila brez predhodnih simptomov preobčutljivosti terapija uvedena ponovno (tj. pri bolnikih, za katere je predhodno veljalo, da prenašajo abakavir).
Contact your doctor immediately: 1 if you get a skin rash, OR 2 if you get symptoms from at least 2 of the following groups: fever shortness of breath, sore throat or cough nausea or vomiting, diarrhoea or abdominal pain severe tiredness or aches and pains, or generally feeling ill.
Takoj se posvetujte z zdravnikom: 1 če se vam pojavi izpuščaj na koži ALI 2 če se vam pojavijo simptomi iz vsaj 2 od naslednjih skupin: povišana telesna temperatura zasoplost, boleče žrelo ali kašelj siljenje na bruhanje ali bruhanje, driska ali bolečine v trebuhu huda utrujenost ali bolečine ali splošno slabo počutje.
The safety and efficacy of Triumeq has not been established in patients with significant underlying liver disorders.
Varnosti in učinkovitosti zdravila Triumeq pri bolnikih s pomembnimi osnovnimi motnjami v delovanju jeter niso dokazali.
Triumeq should not be taken with any other medicinal products containing dolutegravir, abacavir, lamivudine or emtricitabine.
Zdravila Triumeq se ne sme jemati s katerim koli drugim zdravilom, ki vsebuje dolutegravir, abakavir, lamivudin ali emtricitabin.
- The other ingredients are mannitol (E421), microcrystalline cellulose, povidone (K29/32), sodium starch glycolate, magnesium stearate, poly(vinyl) alcohol - partially hydrolysed, titanium dioxide, macrogol/PEG, talc, iron oxide black and iron oxide red).
- Druge sestavine so: manitol (E421), mikrokristalna celuloza, povidon (K29/32), natrijev karboksimetil škrob, magnezijev stearat, poli(vinil) alkohol - delno hidroliziran, titanov dioksid, makrogol/PEG, smukec, črni železov oksid in rdeči železov oksid.
Patients with chronic hepatitis B or C
Bolniki s kroničnim hepatitisom B ali C
If Triumeq is discontinued in patients co-infected with hepatitis B virus, periodic monitoring of both liver function tests and markers of HBV replication is recommended, as withdrawal of lamivudine may result in an acute exacerbation of hepatitis.
Če se pri bolnikih, sočasno okuženih s hepatitisom B, zdravljenje z zdravilom Triumeq prekine, je priporočljivo periodično spremljati tako teste delovanja jeter kot tudi označevalce replikacije virusa HBV, saj lahko ukinitev lamivudina vodi v akutno poslabšanje hepatitisa.
Lamivudine-TP (an analogue for cytidine) and carbovir-TP (the active triphosphate form of abacavir, an analogue for guanosine) are substrates for and competitive inhibitors of HIV reverse transcriptase (RT).
Lamivudin-TP (analog citidina) in karbovir-TP (aktivna trifosfatna oblika abakavirja, analog gvanozina) sta substrata za reverzno transkriptazo (RT) virusa HIV in tudi njena kompetitivna inhibitorja.
DTG/ABC/3TC FDC - abacavir/dolutegravir/lamivudine fixed-dose combination ATV+RTV+TDF/FTC FDC -atazanavir plus ritonavir plus tenofovir disproxil/emtricitabine fixeddose combination
DTG/ABC/3TC FDC - kombinacija fiksnih odmerkov abakavirja/dolutegravirja/lamivudina ATV+RTV+TDF/FTC FDC - kombinacija fiksnih odmerkov atazanavirja in ritonavirja in dizoproksiltenofovirata/emtricitabina
If you forget to take Triumeq
Če ste pozabili vzeti zdravilo Triumeq
Before initiating treatment with abacavir-containing products, screening for carriage of the HLAB*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin (see section 4.4).
Pred uvedbo zdravljenja z zdravili, ki vsebujejo abakavir, je pri vsakem bolniku, okuženim z virusom HIV, treba opraviti presejalni test za prisotnost alela HLA-B*5701, ne glede na rasno poreklo (glejte poglavje 4.4).
CPK elevations, ALT/AST elevations
povišane vrednosti CPK, povišane vrednosti ALT/AST
AUC in cervicovaginal fluid, cervical tissue and vaginal tissue were 6-10% of those in corresponding plasma at steady state.
AUC v cervikovaginalni tekočini, tkivu materničnega vratu in nožničnem tkivu je bila od 6 do 10% ustrezne AUC v plazmi v stanju dinamičnega ravnovesja.
Mitochondrial dysfunction following exposure in utero
Moteno delovanje mitohondrijev po izpostavljenosti in utero
Common side effects that may show up in blood tests are: • an increase in the level of liver enzymes
Pogosti neželeni učinki, ki se lahko pokažejo pri pregledu krvi, so: • povišana vrednost jetrnih encimov
The individual preparations of abacavir and lamivudine have been investigated separately, and as a dual nucleoside backbone, in combination antiretroviral therapy to treat ART- naive and ARTexperienced HIV- infected paediatric patients (data available on the use of abacavir and lamivudine in infants less than three months are limited).
Posamezna zdravila abakavirja in lamivudina so raziskovali posebej, in kot dvojno nukleozidno osnovo, v kombinaciji s protiretrovirusno terapijo za zdravljenje s HIV okuženimi pediatričnimi bolniki, ki predhodno še niso ali so že prejemali ART (razpoložljivi podatki o uporabi abakavirja in lamivudina pri dojenčkih, mlajših od treh mesecev, so omejeni).
Etravirine without boosted protease inhibitors decreased plasma dolutegravir concentration.
Etravirin brez okrepljenih zaviralcev proteaz je zmanjšal koncentracijo dolutegravirja v plazmi.
PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING INTERMEDIATE CARTON (WITHOUT BLUE BOX - COMPONENT OF MULTIPACK)
VMESNA ŠKATLA (BREZ »BLUE BOX« - SESTAVNEGA DELA SKUPNEGA PAKIRANJA)
‡ Includes subjects who discontinued due to an adverse event or death at any time point from Day 1 through the Week 48 analysis window if this resulted in no virologic data on treatment during the analysis window.
‡ Vključuje preiskovance, ki so prenehali sodelovati zaradi neželenega dogodka ali smrti kadar koli v času od 1. dne do zaključenega 48. tedna analize, če zaradi tega ni bilo nobenih viroloških podatkov o zdravljenju v obdobju analize.
If Triumeq is used in patients co-infected with hepatitis B an additional antiviral is, therefore, generally needed.
Če se zdravilo Triumeq uporablja pri bolnikih, ki so sočasno okuženi tudi s hepatitisom B, je običajno treba uporabiti še dodatno protivirusno zdravilo.
Dose reduction is required for patients with creatinine clearance < 50 ml/min (see section 4.2).
Pri bolnikih s kreatininskim očistkom < 50 ml/min je potrebno odmerek zmanjšati (glejte poglavje 4.2).
White HDPE (high density polyethylene) bottles closed with polypropylene child-resistant closures, with a polyethylene faced induction heat seal liner.
Bele plastenke iz HDPE (polietilena visoke gostote) zaprte s polipropilenskimi, z za otroke varnimi zaporkami, zapečatenimi s polietilensko folijo s pomočjo toplotne indukcije.
Hypersensitivity reactions have been reported in <1% of patients treated with dolutegravir in clinical studies, and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including severe liver reactions.
V kliničnih študijah poročajo o preobčutljivostnih reakcijah pri <1% bolnikov, zdravljenih z dolutegravirjem, za katere so bili značilni izpuščaj, sistemski pojavi, včasih pa tudi motnje v delovanju organov, vključno s hudimi jetrnimi reakcijami.
What you need to know before you take Triumeq
Kaj morate vedeti, preden boste vzeli zdravilo Triumeq
1) you get a skin rash OR
1) se vam pojavi izpuščaj na koži ALI
• metformin, to treat diabetes
• metformin za zdravljenje sladkorne bolezni
AUC in semen was 7% and 17% in rectal tissue of those in corresponding plasma at steady state.
AUC v semenu je bila 7% in v tkivu danke 17% ustrezne AUC v plazmi v stanju dinamičnega ravnovesja.
• oxcarbazepine and carbamazepine, to treat epilepsy and bipolar disorder
• okskarbamazepin in karbamazepin, za zdravljenje epilepsije in bipolarne motnje
• difficulty breathing In rare cases, as the immune system becomes stronger, it can also attack healthy body tissue (autoimmune disorders).
V redkih primerih, ko se imunski sistem okrepi, lahko napade tudi zdrava telesna tkiva (avtoimune bolezni).
• lactic acidosis (excess lactic acid in the blood).
• laktacidoza (čezmerno kopičenje mlečne kisline v krvi)
Based on the lack of effect on the in vivo pharmacokinetics of the OAT substrate tenofovir, in vivo inhibition of OAT1 is unlikely.
Zaradi pomanjkanja učinka na farmakokinetiko OAT substrata tenofovirja in vivo zaviranje OAT1 in vivo ni verjetno.
The results showed that there was a mean increase of 1.89-fold [1.32; 2.70] in the abacavir AUC, and 1.58 [1.22; 2.04] fold in the elimination half-life.
Rezultati so pokazali, da je bila AUC abakavirja povečana v povprečju za 1,89-krat [1,32; 2,70], eliminacijski razpolovni čas pa v povprečju za 1,58-krat [1,22; 2,04].
Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg (see sections 4.4 and 5.1).
Zdravilo Triumeq je indicirano za zdravljenje odraslih in mladostnikov, starejših od 12 let, ki tehtajo vsaj 40 kg, okuženih z virusom humane imunske pomanjkljivosti (HIV) (glejte poglavji 4.4 in 5.1).